{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:57Z","timestamp":1761895017635},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.n.083","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T02:02:24Z","timestamp":1262743344000},"page":"417-424","source":"Crossref","is-referenced-by-count":10,"title":["Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials"],"prefix":"10.3816","volume":"9","author":[{"given":"Ji\u0159\u00ed","family":"Pavl\u016f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.083_bib1","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.083_bib2","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.083_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jcp.2008.056804","article-title":"A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia","volume":"61","author":"Khorashad","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.3816\/CLM.2009.n.083_bib4","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.083_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.3816\/CLM.2009.n.083_bib6","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib7","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.083_bib9","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2009.n.083_bib11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1124\/dmd.107.020255","article-title":"Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics","volume":"36","author":"Wang","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.3816\/CLM.2009.n.083_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.083_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.083_bib15","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib16","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (STARTR)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.083_bib17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in he Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.083_bib18","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib19","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.470.470","article-title":"Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005)","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib20","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib21","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.472.472","article-title":"Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program","volume":"110","author":"Gambacorti","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib22","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib23","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.083_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V112.11.3225.3225","article-title":"Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V112.11.3224.3224","article-title":"Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) In patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib26","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V112.11.1006.1006","volume":"112","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V112.11.3226.3226","article-title":"Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-Year Data from CA180-035","volume":"112","author":"Saglio","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib29","doi-asserted-by":"crossref","first-page":"375s","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CMLCP) intolerant to imatinib: a retrospective analysis of safety","volume":"26","author":"Khoury","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.083_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.n.083_bib31","doi-asserted-by":"crossref","first-page":"225a","DOI":"10.1182\/blood.V110.11.734.734","article-title":"Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013)","volume":"110","author":"Stone","year":"2007","journal-title":"Blood"},{"issue":"s1","key":"10.3816\/CLM.2009.n.083_bib32","first-page":"1","article-title":"Dasatinib efficacy in patients with imatinib-resistant\/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L","volume":"93","author":"Porkka","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.083_bib33","doi-asserted-by":"crossref","first-page":"826a","DOI":"10.1182\/blood.V110.11.2810.2810","article-title":"Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015)","volume":"110","author":"Porkka","year":"2007","journal-title":"Blood"},{"issue":"s1","key":"10.3816\/CLM.2009.n.083_bib34","first-page":"371","article-title":"Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"93","author":"Hochhaus","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.083_bib35","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2160.2160","article-title":"Dasatinib (SPRYCEL) in patients with chronic myelogenous leukemia in accelerated phase that is imatinib-resistant or -intolerant: updated results of the CA180-005 START-A phase II study","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.083_bib36","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinibresistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"s1","key":"10.3816\/CLM.2009.n.083_bib37","first-page":"128","article-title":"Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized phase-III trial (CA180034)","volume":"92","author":"Hochhaus","year":"2007","journal-title":"Haematologica"},{"issue":"s1","key":"10.3816\/CLM.2009.n.083_bib38","first-page":"9","article-title":"Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: updated results from CA180015 (START-L) trial","volume":"92","author":"Ottmann","year":"2007","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T12:26:16Z","timestamp":1590495976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1557919011700324"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.083","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}